NMC
ACRV icon

NEA Management Company’s Acrivon Therapeutics ACRV Stock Holding History

NEA Management Company’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-430,252
Closed -$1.29M – 45
2023
Q4 		$1.29M Hold
430,252
– – 0.09% 40
2023
Q3 		$4.11M Sell
430,252
-51,425
-11% -$594K 0.32% 35
2023
Q2 		$6.24M Hold
481,677
– – 0.48% 32
2023
Q1 		$4.89M Hold
481,677
– – 0.34% 37
2022
Q4 		$4.44M Buy
+481,677
New +$6.11M 0.25% 40

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NEA Management Company's ACRV Position: Q1 2024 in Review

NEA Management Company sold out of Acrivon Therapeutics (ACRV) in Q1 2024, closing a stake of 430,252 shares — an estimated $1.29M sold.

NEA Management Company first reported a position in ACRV in Q4 2022 and held it in 5 quarters. The position peaked at $6.24M in Q2 2023. 48 funds tracked by Wall St. Rank hold ACRV as of Q1 2024.

  • NEA Management Company reported no remaining Acrivon Therapeutics position as of Q1 2024 after selling out during the quarter.
  • NEA Management Company sold 430,252 Acrivon Therapeutics shares in Q1 2024, an estimated $1.29M.
  • NEA Management Company first reported a position in Acrivon Therapeutics in Q4 2022 and held it in 5 quarters.
  • NEA Management Company's Acrivon Therapeutics position peaked at $6.24M in Q2 2023.
  • 48 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q1 2024.

Based on NEA Management Company's 13F filing for Q1 2024, filed 15 May 2024.